---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-012020"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2023-04-19T23:59:59+00:00"
generated_at: "2026-06-16T23:49:33.361123+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Abbott Q1 revenue $9.7B, adj EPS $1.03; base business organic growth 10.0%

## Summary
- Q1 GAAP EPS $0.75; adjusted EPS $1.03; revenue $9.747B, down 18.1% reported, but organic base business up 10.0%.
- Full-year 2023 adjusted EPS guidance unchanged at $4.30-$4.50; COVID testing-related sales forecast ~$1.5B.
- Medical Devices organic sales grew 12.4%; FreeStyle Libre sales $1.2B with ~50% U.S. growth.
- Nutrition organic sales up 10.3% (Pediatric +18.4% organic); Diagnostics ex-COVID tests organic +4.4%.
- Dividend of $0.51/share declared, payable May 15; 51 consecutive years of dividend increases.

## SEC filing metadata
- accession: 0001628280-23-012020
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2023-04-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828023012020/0001628280-23-012020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828023012020/abt-20230419.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-012020
- JSON: https://secwatch.observer/filing/0001628280-23-012020.json
- Plain text: https://secwatch.observer/filing/0001628280-23-012020.txt

## Key facts
- Earnings Releases
  ABBOTT LABORATORIES reported first quarter ended March 31, 2023 results: revenue $9.7 billion, EPS First-quarter GAAP diluted EPS of $0.75 and adjusted diluted EPS of $1.03. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $9.7 billion
  - EPS: First-quarter GAAP diluted EPS of $0.75 and adjusted diluted EPS of $1.03
  - Guidance: reaffirmed
  - Result: reported results
  source text: in accordance with GAAP. --- EX-99.1 (EX-99.1) --- 9.1 News Release Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business – Sales of $9.7 billion driven by strong underlying base business performance – Reported sales decreased 18.1 percent due to anticipated decline in COVID-19 testing-related sales versus prior year –
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800/000162828023012020/0001628280-23-012020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.